Patents by Inventor Gunasekaran Kannan

Gunasekaran Kannan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240368236
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: April 18, 2024
    Publication date: November 7, 2024
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Marissa MOCK, Kenneth William WALKER
  • Publication number: 20240327485
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: April 4, 2024
    Publication date: October 3, 2024
    Applicant: Amgen Inc.
    Inventors: Marc Alain GAVIN, Gunasekaran KANNAN, Li Li, Joshua Thomas PEARSON, Margaret KAROW
  • Publication number: 20240327486
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: April 5, 2024
    Publication date: October 3, 2024
    Applicant: Amgen Inc.
    Inventors: Eric Alan BUTZ, Christy Ann THOMSON, Marc Alain GAVIN, Ian Nevin FOLTZ, Dong XIA, Dina N. ALCORN, Randal Robert KETCHEM, Ai Ching LIM, Kathy MANCHULENKO, Laura SEKIROV, Kelly Ann BERRY, Cyr Clovis Chua DE IMUS, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Li LI
  • Patent number: 12102675
    Abstract: The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
    Type: Grant
    Filed: March 14, 2024
    Date of Patent: October 1, 2024
    Assignee: Nutcracker Therapeutics, Inc.
    Inventors: Ole Haabeth, Gunasekaran Kannan
  • Publication number: 20240277827
    Abstract: The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
    Type: Application
    Filed: March 14, 2024
    Publication date: August 22, 2024
    Inventors: Ole HAABETH, Gunasekaran KANNAN
  • Patent number: 12011478
    Abstract: The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: June 18, 2024
    Assignee: Nutcracker Therapeutics, Inc.
    Inventors: Ole Haabeth, Gunasekaran Kannan
  • Publication number: 20240150736
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis S. KARIOLIS, Cathal S. MAHON
  • Publication number: 20240148866
    Abstract: Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 9, 2024
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Annie ARGUELLO, Tina GIESE, Gunasekaran KANNAN, Mihalis S. KARIOLIS, Cathal S. MAHON, Junhua WANG
  • Patent number: 11976103
    Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: May 7, 2024
    Assignee: Amgen Inc.
    Inventors: Eric Alan Butz, Christy Ann Thomson, Marc Alain Gavin, Ian Nevin Foltz, Dong Xia, Dina N. Alcorn, Randal Robert Ketchem, Ai Ching Lim, Kathy Manchulenko, Laura Sekirov, Kelly Ann Berry, Cyr Clovis Chua De Imus, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Li Li
  • Patent number: 11976102
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 7, 2024
    Assignee: Amgen Inc.
    Inventors: Marc Alain Gavin, Gunasekaran Kannan, Li Li, Joshua Thomas Pearson, Margaret Karow
  • Patent number: 11919964
    Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: March 5, 2024
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Ling Liu, Edward J. Belouski, Cen Xu
  • Patent number: 11884944
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: January 30, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Tina Giese, Gunasekaran Kannan, Mihalis S. Kariolis, Cathal S. Mahon
  • Publication number: 20230381276
    Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
    Type: Application
    Filed: December 1, 2022
    Publication date: November 30, 2023
    Applicant: AMGEN INC.
    Inventors: Khaled M.K.Z. ALI, Neeraj Jagdish AGRAWAL, Gunasekaran KANNAN, Ian FOLTZ, Zhulun WANG, Darren BATES, Marissa MOCK, Shunsuke TAKENAKA
  • Patent number: 11739131
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: August 29, 2023
    Assignee: AMGEN INC.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • Publication number: 20230265137
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 24, 2023
    Publication date: August 24, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • Publication number: 20230192887
    Abstract: In one aspect, bispecific proteins having the ability to specifically bind to both subdomain II of human HER2 and subdomain IV of human HER2 are provided. In another aspect, methods of treating a cancer or treating brain metastasis of a cancer using a bispecific protein that specifically binds to subdomain II and subdomain IV of human HER2 are provided.
    Type: Application
    Filed: August 11, 2022
    Publication date: June 22, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gunasekaran Kannan, Do Jin Kim, Wanda Kwan, Raymond Ka Hang Tong
  • Patent number: 11643446
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: May 9, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • Publication number: 20230128444
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: September 28, 2022
    Publication date: April 27, 2023
    Applicant: AMGEN INC.
    Inventors: Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne H. TSUJI
  • Publication number: 20230062800
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 2, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON
  • Patent number: 11541103
    Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: January 3, 2023
    Assignee: Amgen Inc.
    Inventors: Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Darren Bates, Marissa Mock, Shunsuke Takenaka